Enhancing Patient-Centred Health Technology Assessment in Europe
A POLICY BRIEFING | MAY 2026
The EU Health Technology Assessment Regulation has changed how new medicines and treatments are assessed across Europe.
People with lived experience now have a formal role in parts of the process, helping decision-makers understand how treatments affect daily life as well as what the clinical evidence shows.
This policy briefing explains how the EU process works, where people affected by lung cancer and patient organisations can contribute, and how Lung Cancer Europe is supporting greater involvement.
Key Points
The EU Health Technology Assessment Regulation creates a shared European process for assessing the clinical evidence for new medicines and health technologies.
People affected by lung cancer can contribute lived experience through Joint Clinical Assessments and Joint Scientific Consultations.
This input can help decision-makers understand the impact of a treatment beyond clinical trial results alone.
Lung Cancer Europe is working to make the process easier to understand and to support lung cancer representatives to take part.
